Mitsubishi Chemical Holdings is entering into the regenerative medicine business. Its subsidiary Life Science Institute, Inc. (LSII) has announced on the 14th that they have bought out Clio (Akita-city), the regenerative medicine venture, and making it as their consolidated subsidiary. They are planning to start the clinical experiment using Clio’s techniques in 2016, and commercializing it as early as in fiscal year 2020. Mitsubishi Chemical HD considers the regenerative medicine as a long term growing field, and therefore they have been speeding up to invest its development.

An estimated buying out price is around 2-3 billion yen. Clio has an exclusive license on the adult stem cell that was discovered by the research team at Tohoku University. The stem cell naturally resides inside a body. Furthermore, the stem cell has a high regenerative capacity—they can differentiate an array of tissues. LSII is hoping to develop the effects of restoring the damaged tissues from myocardial infarctions, cirrhosis and so on.

Mr Seiichi Kiso, the CEO of LSII has remarked ‘it has such a growing potential’ at his press conference. He is going to raise the presence in the field of the regenerative medicine by using a different type of stem cell from iPS cell. They will intensively invest for the clinical research in order to start the clinical experiment in fiscal year 2016. They are starting its product sales in fiscal year 2020, targeting around 10 billion yen as its turnover by fiscal year 2025. They are considering the overseas expansion as well.

Life Science Institute, Inc. (LSII) was established on April 1, 2014 with a view to enhancing and expanding the Mitsubishi Chemical Holdings Corporation (MCHC) Group’s healthcare businesses. LSII has been working on drug discovery supports, pharmaceutical capsules and so on, and its turnover was 129.3 billion yen in fiscal year 2014. They have been enthusiastic about introducing the regenerative medicine as a ‘next generation’s medicine.